Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Instinctif Partners

06:00 EDT 21st October 2018 | BioPortfolio

Here are the most relevant search results for "Instinctif Partners" found in our extensive news archives from over 250 global news sources.

More Information about Instinctif Partners on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Instinctif Partners for you to read. Along with our medical data and news we also list Instinctif Partners Clinical Trials, which are updated daily. BioPortfolio also has a large database of Instinctif Partners Companies for you to search.

Showing News Articles 1–25 of 740 from Instinctif Partners

Thursday 18th October 2018

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

Cambridge, UK, 18 October 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer. Richard will manage Crescendo’s internal CMC act...

Tuesday 16th October 2018

DNAe Wins OBN Award for Best Diagnostic Medtech Company

London, UK and Carlsbad, CA, USA – 16 October 2018 – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, was named ‘Best Diagnostic Medtech Company’ at the 2018 OBN Awards. Marking its 10th anniversary, the prestigious OBN Awards recognize and cel...

Monday 15th October 2018

F-star Appoints Dr Eliot Forster as Chief Executive Officer.

Cambridge, UK – 15 October 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum. Eliot brings more than 25 years of extensive leadership experience ...

Thursday 11th October 2018

Doubts Over Data Security Denting Smart Inhaler Potential?

Cambridge, UK – 11 October 2018 – As many as 800 asthma deaths a year in the UK could be prevented by a new generation of ‘smart inhalers’, however, data concerns could be holding back roll out, says medical device developer and manufacturer, Bespak. Michael Earl, Commercial Director at Bespak commented, “Data shows that nearly all patients don’t always use ...

Tuesday 9th October 2018

New PBS-Only Antibodies Enable More Flexible Research

Cambridge, UK – 9 October 2018 – Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments. Typically, antibodies are stored in a buffer composed of bovine serum albumin (BSA), glycerol and sodium azide to ensure stability. However...

Monday 8th October 2018

European Society for Medical Oncology President joins Imugene Scientific Advisory Board

Sydney, Australia - 8 October 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Dr Josep Tabernero, the President of the European Society for Medical Oncology, to its Scientific Advisory Board. The European Society for Medical Oncology (ESMO) is the world’s leading professional organisation for medical oncology with 18,000...

Thursday 4th October 2018

New oral liquids facility at Pianezza: and enhanced blister and packaging line at Monheim

European Facility Updates from Consort Medical New oral liquids facility at Pianezza: and enhanced blister and packaging line at Monheim Hemel Hempstead, UK – Consort Medical, Aesica CDMO Services, announces key facility updates for manufacturing and packaging solutions at both its Pianezza and Monheim sites. The redesigned oral liquids facility, at Pianezza, features the latest Mar...

Wednesday 3rd October 2018

Leading Pharma Executive Kate Hilyard Joins Healx to Drive the Integration of AI with Drug Discovery for Rare Diseases

Cambridge, UK – 2 October, 2018 – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced the appointment of Kate Hilyard PhD as Chief Operating Officer (COO). A senior pharma executive, with extensive drug discovery expertise, Kate’s appointment underlines Healx’s mission to combine deep pharmacological experti...

Trading update – commercial progress and US market strategy

Cambridge, 3 October 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces a trading update for the year ended 31 May 2018 and the period to 30 September 2018. The Company is seeing improving trading conditions following a year of structural change and investment. Highlights Placing in March 2018 rais...

Thursday 27th September 2018

DNAe Wins Inaugural 2018 Medtech Insight Top Innovator Award

London, UK and Carlsbad, CA, USA – 27 September 2018 – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, was named ‘Most Innovative Team or Innovator of the Year’ at the inaugural 2018 Medtech Insight Awards. The Most Innovative Team or Innovat...

Friday 21st September 2018

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases.

Oxford, UK, 20 September 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU ...

Wednesday 19th September 2018

SkinBioTherapeutics plc: Human study commenced

Manchester, UK – 19 September 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, confirms that it has commenced its human study being carried out on its SkinBiotix® technology. There are three elements to the human study: the first, already underway, is to assess skin irritancy; the second, due to commence on 20...

Tuesday 11th September 2018

Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer

Cambridge, UK, 11 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect. Pavel Pisa is the former Head of Translational Medicine at Roche and Genentech and has led over 50 programmes through earl...

Monday 10th September 2018

Biopharma Company Arecor raises £6m for revolutionary diabetes treatments

10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures.  BioScience Managers Limited, the international healthcare investment firm...

TexRAD® ordered by Samsung Medical Centre in South Korea

Cambridge, UK, 10 September 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for TexRAD®, its patented image texture analysis technology, for the Samsung Medical Centre in Seoul. The order cam...

Thursday 6th September 2018

LEUKOCARE and Xellia Pharmaceuticals partner to discover innovative formulations for the development of value-added anti-infective therapies

September 6th 2018: LEUKOCARE AG and Xellia Pharmaceuticals, have entered into a global strategic partnership, where both companies will collaborate closely to discover innovative and superior formulations to support the development of Xellia’s pipeline of value-added antibiotic and antifungal products which are intended to enhance patient care. Munich, Germany and Copenhagen, Denmark...

Tuesday 4th September 2018

Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medi

CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immed...

Monday 3rd September 2018

SkinBioTherapeutics: SkinBiotix® technology successful in stability testing

Manchester, UK – 03 September 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, is pleased to provide an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned. Dr Cath O’Neill, CEO...

Tuesday 28th August 2018

Congenica - Appoints Wendy Britten as Chief Financial Officer

Cambridge, United Kingdom – 28 August, 2018 – Congenica, the global provider of clinical genomics interpretation software, today announced the appointment of Mrs Wendy Britten as its new Chief Financial Officer (CFO), effective 1st September, 2018. Mrs Britten will have overall control and responsibility for all financial aspects of the business and will play a key role in busines...

Thursday 16th August 2018

Immatics Initiates Second Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Houston, Texas, August 16th , 2018 – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA202, its second T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA202 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based...

SkinBioTherapeutics plc - Business update - manufacturing scale-up and financial position

Manchester, UK – 16 August 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health,  is pleased to provide the following update: Manufacturing The Company, with its third party manufacturer, has now achieved significant manufacturing scale up, with no detrimental impact upon the active properties of the SkinBiot...

Wednesday 15th August 2018

DNAe Chosen as Best Diagnostic Medtech Company Finalist in the 2018 OBN Awards

London, UK and Carlsbad, CA, USA – 15 August 2018 – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, today announced that it has been shortlisted as a finalist for the 2018 OBN Awards, in the category ‘Best Diagnostic Medtech Company’. These p...

Crescendo Biologics Ltd Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda

Cambridge, UK, 15 August 2018 – Crescendo Biologics Ltd (Crescendo), the developer of targeted T-cell engagers, today announced that it has achieved another technical milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE:4502). Crescendo’s global, strategic, multi-target collaboration and license agreement with Takeda was announced in October 201...

Feedback plc: First GE Healthcare order for TexRAD® medical imaging software

15th August 2018: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received its first order via GE Healthcare (GEHC) for TexRAD®, its patented image texture analysis technology. The order follows the distribution agreement announced on 25 April 2018,...

Tuesday 14th August 2018

DNAe Named as Top Innovator Finalist in the Inaugural 2018 Medtech Insight Awards

London, UK and Carlsbad, CA, USA – 8 August 2018 – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, today announced that it has been shortlisted for the inaugural 2018 Medtech Insight Awards, in the category ‘Most Innovative Team or Innovator of the...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks